This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash all over torso and body/itchy rash), SWELLING (swelling of nose), LIP SWELLING (swelling of lips), DIZZINESS (Dizziness) and NAUSEA (Nausea) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.  NO Medical history information was reported. On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced RASH (rash all over torso and body/itchy rash), SWELLING (swelling of nose), LIP SWELLING (swelling of lips), DIZZINESS (Dizziness) and SWELLING FACE (swollen face). On 16-Feb-2021, the patient experienced NAUSEA (Nausea). On 16-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (didn't receive the vaccine after 9 weeks (63 days)). The patient was treated with NAPROXEN SODIUM (NAPROXENE [NAPROXEN SODIUM]) at a dose of UNK, qd and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of UNK, qd. On 17-Feb-2021, NAUSEA (Nausea) had resolved. On 16-Apr-2021, PRODUCT DOSE OMISSION ISSUE (didn't receive the vaccine after 9 weeks (63 days)) outcome was unknown. At the time of the report, RASH (rash all over torso and body/itchy rash), SWELLING (swelling of nose), LIP SWELLING (swelling of lips), DIZZINESS (Dizziness) and SWELLING FACE (swollen face) outcome was unknown.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Feb-2021, Heart rate: High. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. NO concomitant medication was reported. Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: Follow up-1 received on 16-APR-2021, the information included: postal address was updated, event(s) date changed, the outcome of the event was changed, treatment medications were updated. This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 18-Feb-2021. The most recent information was received on 16-Apr-2021 and was forwarded to Moderna on 16-Apr-2021. This spontaneous case was reported by a consumer and describes the occurrence of RASH (rash all over torso and body/itchy rash), SWELLING (swelling of nose), LIP SWELLING (swelling of lips), DIZZINESS (Dizziness) and NAUSEA (Nausea) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. NO Medical history information was reported. On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced RASH (rash all over torso and body/itchy rash), SWELLING (swelling of nose), LIP SWELLING (swelling of lips), DIZZINESS (Dizziness) and SWELLING FACE (swollen face). On 16-Feb-2021, the patient experienced NAUSEA (Nausea). On 16-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (didn't receive the vaccine after 9 weeks (63 days)). The patient was treated with NAPROXEN SODIUM (NAPROXENE [NAPROXEN SODIUM]) at a dose of UNK, qd and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of UNK, qd. On 17-Feb-2021, NAUSEA (Nausea) had resolved. On 16-Apr-2021, PRODUCT DOSE OMISSION ISSUE (didn't receive the vaccine after 9 weeks (63 days)) outcome was unknown. At the time of the report, RASH (rash all over torso and body/itchy rash), SWELLING (swelling of nose), LIP SWELLING (swelling of lips), DIZZINESS (Dizziness) and SWELLING FACE (swollen face) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 16-Feb-2021, Heart rate: High. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. NO concomitant medication was reported. Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: Follow up-1 received on 16-APR-2021, the information included: postal address was updated, event(s) date changed, the outcome of the event was changed, treatment medications were updated.